City of Hope | Strategic Alliance Partners

Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.

Michael A. Rosenzweig, MD, MS, discusses changes in the frontline setting of multiple myeloma.

David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

Tanya Siddiqi, MD, explains how novel agents are improving the treatment landscape for chronic lymphocytic leukemia, citing examples from the TRANSCEND CLL 004 trial.

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the CLL14 trial, which tested venetoclax (Venclexta) plus obinutuzumab (Gazyva) versus obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions.

With its long-standing commitment to patients, the designation makes City of Hope the highest ranked cancer hospital in the West.

PD-L1–positive natural killer cells may prove to be another important immune effector cell for checkpoint inhibitor-based cancer immunotherapy.

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Larry Kwak, MD, PhD, has been appointed the deputy director of City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.

Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.

Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.